ReviewFrontiers in pharmacology2025
Organoids: their emerging essential role in pathological mechanisms and drug discovery of diabetes and its complications.
Review in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Bioengineering Pancreatic Organoids and iPSC-Derived β-Cells for Diabetes: Materials, Devices, and Translational Challenges.Bioengineering (Basel, Switzerland) · 2026Review
- Endocrinology at a Miniature Level: Pluripotent Stem-Cell-Derived Organoid Models of Hypothalamus-Pituitary Axes.Biomolecules · 2026Review
- Metabolic reprogramming in diabetes and cancer: the role of PI3K/AKT/mTOR and beyond.American journal of cancer research · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diabetes mellitus is a metabolic disease with a high global prevalence, which affects blood vessels throughout the entire body. As the disease progresses, it often leads to complications, including diabetic retinopathy and nephropathy. Currently, in addition to traditional cellular and animal models, more and more organoid models have been used in the study of diabetes and have broad application prospects in the field of pharmacological research. We summarized the organoid models that have been developed for the study of diabetes mellitus and its complications, and describe their sources, establishment and maturation measures with a focus on pancreatic organoids. For the first time, we summarized the contribution of organoids in diabetes and its complications in terms of mechanism studies, drug screening, and cellular replacement therapies, in the hope of providing a feasible direction for personalized medicine and precision treatment of diabetes and its complications. In addition, we discuss the strengths and limitations of organoids in the field of diabetes and its complications. Nowadays, people strongly advocate personalized medicine and precision medicine, and in this regard, organoid technology has advantages that are unmatched by any conventional experimental models. By combing organoid technology with high-throughput technologies, "patient-specific" drug screening can be achieved faster and more accurately. Organoids are also becoming a potential source of transplantable tissues and functional cell types for cellular replacement therapies in regenerative medicine. With further development of assembly and vascularization techniques, organoids will gradually mature and improve. In conclusion, the 3D organoid system greatly complements the existing modeling system and may play a significant role in future basic and clinical research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.